Group 1 - The company, Zhonghui Biotech-B (02627), plans to conduct an initial public offering (IPO) from July 31 to August 5, 2025, with a global offering of 33.44 million H-shares, where 10% will be offered in Hong Kong and 90% internationally [1] - The offering price per share is set between HKD 12.9 and HKD 15.5, with trading expected to commence on August 8, 2025 [1] - The company focuses on the research, development, manufacturing, and commercialization of innovative vaccines and traditional vaccines using new technologies, aiming to replace traditional and imported vaccines in China and expand its competitive advantage internationally [1] Group 2 - The cornerstone investors, including Jiaxing Xinyang and Huatai Capital Investment, have agreed to subscribe for shares worth approximately USD 13 million, with an estimated subscription of 7.1136 million H-shares at a midpoint offering price of HKD 14.20 per share [2] - This subscription represents about 21.3% of the total shares offered in the global offering, assuming no exercise of the over-allotment option [2] - The estimated net proceeds from the global offering, after deducting underwriting fees and expenses, is approximately HKD 421 million [2] Group 3 - The company plans to allocate approximately 63.6% of the net proceeds from the global offering to the development and registration of its core products, with specific allocations for ongoing research and overseas registration of the quadrivalent influenza virus subunit vaccine and the Phase III clinical trial of the freeze-dried rabies vaccine [3] - About 18.1% will be used for the development and registration of other pipeline vaccines, while 8.4% will enhance production and commercialization capabilities [3] - Additionally, 4.9% will be allocated for the development and operation of various technological platforms, and 5.0% will be used for working capital and general corporate purposes [3]
中慧生物-B于7月31日至8月5日招股 拟全球发售3344.26万股H股